| abstract |
The present invention provides pharmaceutical compositions, dosage forms, and novel forms of compounds of formula (I), and methods of use thereof. The present invention relates to [[5-chlorothiophen-2-ylsulfonylcarbamoyl)-(4- (6-fluoro-7- (methylamino) -2,4-dioxo-1,2-dihydroquinazoline- 3 (4H) - yl) thereof phenyl) novel crystalline anhydrous form of the amide potassium salt, and animals, particularly in the inhibition of platelet ADP receptors in humans, especially treatment or prophylaxis of conditions or disorders associated with the inhibition of P2Y 12 Regarding use. The present invention also relates to a process for producing such a novel crystalline form. The invention also relates to this novel crystalline form of solid oral formulation, its preparation and its use. [Selection figure] None |